Myeloid Malignancy Clinical Trials

14 recruiting

Myeloid Malignancy Trials at a Glance

14 actively recruiting trials for myeloid malignancy are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Hangzhou, Shanghai, and Zhengzhou. Lead sponsors running myeloid malignancy studies include First Affiliated Hospital of Zhejiang University, University of Rochester, and Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

Browse myeloid malignancy trials by phase

Treatments under study

About Myeloid Malignancy Clinical Trials

Looking for clinical trials for Myeloid Malignancy? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myeloid Malignancy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myeloid Malignancy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 1Phase 2

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.682 enrolled12 locationsNCT04501120
Recruiting
Phase 1Phase 2

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Acute Myeloid LeukemiaMyeloid Malignancy
Benjamin Tomlinson20 enrolled2 locationsNCT06129734
Recruiting
Not Applicable

Germline Testing for Predisposition to Myeloid Malignancies

Genetic Predisposition to DiseaseMyeloid MalignancyMyeloid Hematological Malignancies
Christopher Reilly200 enrolled1 locationNCT07112287
Recruiting
Not Applicable

A Telehealth Advance Care Planning Intervention

Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelofibrosis+2 more
University of Rochester207 enrolled1 locationNCT05875805
Recruiting
Not Applicable

Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories

Myeloid Malignancy
University of Rochester120 enrolled1 locationNCT07263074
Recruiting
Phase 1

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

Acute Myeloid LeukemiaHematologic MalignancyMyelodysplastic Syndromes+1 more
University of Alabama at Birmingham20 enrolled1 locationNCT07044544
Recruiting
Phase 2

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Myeloid Malignancy
Henry Ford Health System43 enrolled1 locationNCT03850418
Recruiting
Not Applicable

Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

Hematopoietic and Lymphatic System NeoplasmHematologic NeoplasmsMyeloid Malignancy+10 more
Mayo Clinic2,000 enrolled3 locationsNCT02958462
Recruiting
Phase 2

Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML

Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
First Affiliated Hospital of Zhejiang University72 enrolled1 locationNCT06621212
Recruiting
Phase 1

A Study of GLB-001 in Patients With Myeloid Malignancies

Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelofibrosis+3 more
Hangzhou GluBio Pharmaceutical Co., Ltd.108 enrolled14 locationsNCT06378437
Recruiting
Phase 1

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

Acute Myeloid LeukemiaMyelodysplastic SyndromesMyeloid Malignancy
Masonic Cancer Center, University of Minnesota45 enrolled1 locationNCT06594445
Recruiting
Phase 1Phase 2

A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies

Myeloid Malignancy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.138 enrolled21 locationsNCT07011186
Recruiting
Phase 2

Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.

Myeloid MalignancyHypomethylating AgentVenetoclax
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine78 enrolled1 locationNCT05841771
Recruiting
Phase 2

Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML

Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
First Affiliated Hospital of Zhejiang University34 enrolled1 locationNCT06434662